The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

Transcription

1 Brochure More information from The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011 Description: The market for therapeutic monoclonal antibodies (mabs) is one of the most dynamic sectors within the pharmaceutical industry. Next generation antibodies are forecast to drive the market towards the $30 billion mark by 2011 due to a high level of innovation in early-stage discovery and several potential nichebusters set to launch in the next 5 years. The Future of Monoclonal Antibody Therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011, is a unique report that combines up-to-date analysis of the current antibodies market with detailed insights into therapeutic, technology, discovery and drug delivery trends set to shape the market in the next 5 years and beyond. Gain access to the most comprehensive data on the antibody market and take advantage of exclusive insights into research trends from early stage discovery to marketed drugs. Key Findings Of This Report: - The antibody market is set to more than double in value over the next 5 years to $29.7bn, continuing the rapid growth witnessed in the past 2 years. - During the next 5 years antibodies for oncology and arthritis, immune and inflammatory disorders (AIID) are forecast to continue to lead the market, with sales of $14bn and $11bn, respectively in With the predicted launch of 2 pipeline antibodies in the next 5 years, the infectious disease area is set to grow in importance. Antibodies are also being developed in respiratory, cardiovascular and ophthalmology indications. - Analysis of early and late stage pipelines show development focus is shifting away from murine and chimeric mabs to humanized and fully human antibodies. Abbott/CAT s Humira, launched in the US in 2003, was the first fully human antibody on the market. - Genentech and Roche held a combined 48.7% share of the antibodies market in 2005, primarily due to the success of their collaborative oncology drugs, Rituxan, Herceptin and Avastin. Key Questions Answered In This Report: - What were the key events in the global mab market in ? - What are the opportunities and threats to key players in this market? - Which companies are innovators in the mab market and who have they formed collaborations with? - What is the sales forecast in each therapy area of the mab market over the period ? - What are current and future leading brands in the global mab market? - What strategies are the leading companies implementing to maximize sales and boost market share? - Which new product launches are forecast to gain blockbuster status? Reasons to Order your Copy Today: - Assess the sales growth potential of antibodies in each therapeutic market through the 5-year forecasts in oncology, AIID, infectious diseases, respiratory, cardiovascular and ophthalmology indications. - Evaluate the future of the monoclonal antibodies market in 2011 and assess your potential competitive position, through the report s extensive pipeline insight and profiles of upcoming launches. - Implement strategies to overcome the key current and future challenges in the antibodies market, including issues of pricing and reimbursement, competition from targeted small molecule drugs and the threat of biosimilars. - Anticipate future trends in the market by using the report s in-depth analysis of innovation in drug discovery platforms, antibody engineering and non-invasive drug delivery. - Identify the critical success factors for your company to succeed in the antibody market, through examination of successful growth strategies used by the leading antibody drug developers and technology innovators

2 Contents: Executive Antibody engineering and innovation in the market The current monoclonal antibody market The antibody pipeline and forecasts to 2011 Competitive landscape and future growth strategies Chapter 1 History of monoclonal antibodies Monoclonal antibody approval process Current approval process Biogeneric regulations Key trends in the market Advancements in innovation Diversification of therapy areas Big Pharma entering the mab market Chapter 2 Antibody engineering and innovation in the market 28 The move from murine to fully human mabs Whole IgG monoclonal antibodies Murine Chimeric Humanized Human Innovations in antibody structures Fab fragments Single chain variable fragments Extended release formulations Innovation in antibody conjugation Types of conjugation Direct arming: antibody conjugation Indirect arming: Bispecific monoclonal antibodies Pre-targeting Marketed conjugated monoclonal antibodies Conjugation technology Seattle Genetics antibody technology ImmunoGen mab technology Peregrine mab technology Enhancing monoclonal antibody potency Drug discovery Cambridge Antibody Technology Dyax Morphosys Innovation in drug delivery Drug delivery devices Inhaled monoclonal antibodies Oral monoclonal antibodies Chapter 3 The current monoclonal antibody market Strategic analysis Drivers Pipeline drugs Immature market Big Pharma entering the mab market High level of innovation Approval of new indications

3 Combination therapies Resistors Publicized side effects Drugs suspended from market Competition from small molecule drugs Pricing and reimbursement schemes Analysis of launched drugs Oncology Rituxan Herceptin Avastin Erbitux Campath Zevalin MyloTarg Bexxar AIID Remicade Humira Raptiva Simulect Zenapax OrthoClone OKT3 Hemostasis ReoPro Anti-infectives Synagis Respiratory Xolair Marketed monoclonal antibody forecasts Chapter 4 The antibody pipeline and forecasts to 2011 Strategic analysis Opportunities Clinical trials Erbitux and Avastin Simulect, Zenapax and Campath Campath Others Innovation in antibody engineering New indications Challenges Generic biologics Adverse reactions in clinical trials, side effects and termination of development High attrition rates Analysis of pipeline drugs AIID Cimzia MRA/Actemra Eculizumab AMG-162 Cardiovascular Pexelizumab Infectious diseases Numax Oncology ABX-EGF MDX-010+MDX-1379 Humax Ophthalmology Lucentis

4 Late stage pipeline forecasts The antibody market in 2011 Chapter 5 Competitive landscape and future growth strategies Key players in the monoclonal antibody market M&A and licensing activity Big Pharma acquiring biotechs and antibody companies AstraZeneca and CAT Novartis and NeuTec Amgen and Abgenix Roche and GlycArt MedImmune and Cellective Therapeutics Pfizer and Bioren Company profiles Big Pharma Roche Pipeline Novartis Pipeline Pfizer Pipeline Large biotech Genentech Pipeline MedImmune Company Profile Biogen Idec Strategic analysis UCB-Celltech Small biotech/antibody companies Medarex XOMA

5 Technology companies BioWa Crucell Chapter 6 Appendix Sales data Index List of Figures Figure 1.1: History of monoclonal antibodies Figure 2.2: Current marketed monoclonal antibodies, 2006 Figure 2.3: Therapeutic mabs entering clinical study, Figure 2.4: Whole antibody and fragment structures Figure 3.5: Drivers and resistors to growth in the monoclonal antibody market Figure 3.6: Market dynamics of current marketed drugs, Figure 3.7: Marketed monoclonal antibodies by therapy area, 2006 Figure 4.8: Opportunities and challenges in the mab market Figure 4.9: Antibody structure analysis of forecasted monoclonal antibody sales ($m), Figure 4.10: Therapy area analysis in monoclonal antibody drug development, 2006 Figure 4.11: Therapy area analysis of forecasted monoclonal antibody sales ($m), Figure 5.12: Key growth strategies in the monoclonal antibody market, Figure 5.13: Roche s SWOT analysis in the mab market Figure 5.14: Novartis SWOT analysis in the mab market Figure 5.15: Pfizer s SWOT analysis in the mab market Figure 5.16: Genentech s SWOT analysis in the mab market Figure 5.17: MedImmune s SWOT analysis in the mab market Figure 5.18: Biogen Idec s SWOT analysis in the mab market Figure 5.19: UCB Celltech s SWOT analysis in the mab market Figure 5.20: Medarex s SWOT analysis in the mab market Figure 5.21: XOMA s SWOT analysis in the mab market Figure 5.22: BioWa s SWOT analysis in the mab market Figure 5.23: Crucell s SWOT analysis in the mab market List of Tables Table 1.1: Current marketed drugs, 2006 Table 1.2: Key players in the monoclonal antibody market, 2006 Table 2.3: Marketed therapeutic monoclonal antibodies, Table 2.4: Antibody fragment pipeline, 2006 Table 2.5: Conjugated antibody engineering technology Table 2.6: Drug development technology Table 2.7: Monoclonal antibody drug discovery technology Table 3.8: Marketed therapeutic monoclonal antibodies, Table 3.9: Marketed monoclonal antibody sales forecasts, Table 4.10: Other post-marketing clinical trials, Table 4.11: Late stage monoclonal antibody pipeline, 2006 Table 4.12: Late stage monoclonal antibody pipeline sales forecast to 2011 Table 5.13: Key players in the monoclonal antibody market, 2006 Table 5.14: Monoclonal antibody collaborations, manufacturing, development and supply agreements, Table 5.15: Key acquisitions in the monoclonal antibody market, Table 5.16: Roche s marketed monoclonal antibodies, 2006 Table 5.17: Roche s monoclonal antibody pipeline, 2006 Table 5.18: Novartis marketed monoclonal antibodies, 2006 Table 5.19: Novartis monoclonal antibody pipeline, 2006 Table 5.20: Pfizer s monoclonal antibody pipeline, 2006 Table 5.21: Genentech s marketed monoclonal antibodies, 2006 Table 5.22: Genentech s monoclonal antibody pipeline, 2006

6 Table 5.23: MedImmune s marketed monoclonal antibodies, 2006 Table 5.24: MedImmune s monoclonal antibody pipeline, 2006 Table 5.25: Biogen Idec s marketed monoclonal antibodies, 2006 Table 5.26: Biogen Idec s monoclonal antibody pipeline, 2006 Table 5.27: UCB-Celltech monoclonal antibody pipeline, 2006 Table 5.28: Medarex s monoclonal antibody pipeline, 2006 Table 5.29: XOMA s monoclonal antibody pipeline, 2006 Table 5.30: BioWa s monoclonal antibody pipeline, 2006 Table 5.31: Crucell s monoclonal antibody pipeline, 2006 Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

7 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to SC Product Formats Please select the product formats and quantity you require: Electronic (PDF) - Single User: Electronic - Enterprisewide: Quantity USD 2875 USD Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

8 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World